Compounds > sb 204990
Page last updated: 2024-11-12

sb 204990

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10340264
CHEMBL ID121446
SCHEMBL ID15320468
MeSH IDM0291686

Synonyms (20)

Synonym
+-(3r*,5s*)-3-carboxy-11-(2,4-dichlorophenyl)-3,5-dihydroxyundecanoic acid
154566-12-8
3-furanacetic acid, 5-(6-(2,4-dichlorophenyl)hexyl)tetrahydro-3-hydroxy-2-oxo-, trans-(+-)-
sb 204990
sb-204990
CHEMBL121446
SCHEMBL15320468
(3r,5s)-rel-5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanacetic acid
AKOS024458437
CS-0006344
HY-16450
2-[(3s,5r)-5-[6-(2,4-dichlorophenyl)hexyl]-3-hydroxy-2-oxooxolan-3-yl]acetic acid
(3r,5s)-rel-5-[6-(2,4-dichlorophenyl)hexyl]tetrahydro-3-hydroxy-2-oxo-3-furanaceticacid
MS-26461
154566-58-2
(-)sb-204990
EX-A6876
154566-55-9
EX-A6877
(+)sb-204990
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID86533Inhibition of ATP levels in HepG2 cells was measured at 15 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86543Inhibition of cholesterol synthesis in HepG2 cells was measured at 15 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86546Inhibition of cholesterol synthesis in HepG2 cells was measured at 5 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID311046Inhibition of fatty acid synthesis in rat2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
The biology and chemistry of hyperlipidemia.
AID86710Inhibition of cholesterol synthesis in HepG2 cells was measured at 30 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID1408679Inhibition of ACLY in human HepG2 cells assessed as reduction in cholesterol synthesis at 30 uM relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID86551Inhibition of fatty acid synthesis in HepG2 cells was measured at 15 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID1408685Antiproliferative activity against human A549 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID1408686Antiproliferative activity against human SKOV3 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID86556Inhibition of fatty acid synthesis in HepG2 cells was measured at 5 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID187614% Reduction of plasma triglyceride in the rat was measured at dose 75 mg/kg/d1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86553Inhibition of fatty acid synthesis in HepG2 cells was measured at 30 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID311043Inhibition of cholesterol synthesis in human HepG2 cells2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
The biology and chemistry of hyperlipidemia.
AID187613% Reduction of plasma triglyceride in the rat was measured at dose 37.5 mg/kg/d1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86535Inhibition of ATP levels in HepG2 cells was measured at 3 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID1408674Antiproliferative activity against human PC3 cells2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID86713Inhibition of fatty acid synthesis in HepG2 cells was measured at 15 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID311044Inhibition of fatty acid synthesis in human HepG2 cells2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
The biology and chemistry of hyperlipidemia.
AID86540Inhibition of cholesterol synthesis in HepG2 cells was measured at 100 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID311045Inhibition of cholesterol synthesis in rat2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
The biology and chemistry of hyperlipidemia.
AID86539Inhibition of cholesterol synthesis in HepG2 cells was measured at 10 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86547Inhibition of fatty acid synthesis in HepG2 cells was measured at 10 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86530Inhibition of ATP levels in HepG2 cells was measured at 10 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86552Inhibition of fatty acid synthesis in HepG2 cells was measured at 3 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86536Inhibition of ATP levels in HepG2 cells was measured at 30 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86538Inhibition of ATP levels in HepG2 cells was measured at 5 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86531Inhibition of ATP levels in HepG2 cells was measured at 100 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86548Inhibition of fatty acid synthesis in HepG2 cells was measured at 100 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID86544Inhibition of cholesterol synthesis in HepG2 cells was measured at 3 uM concentration.1998Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19
ATP-Citrate lyase as a target for hypolipidemic intervention. 2. Synthesis and evaluation of (3R,5S)-omega-substituted-3-carboxy-3, 5-dihydroxyalkanoic acids and their gamma-lactone prodrugs as inhibitors of the enzyme in vitro and in vivo.
AID1408680Inhibition of ACLY in human HepG2 cells assessed as reduction in fatty acid synthesis at 30 uM relative to control2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (25.00)18.2507
2000's4 (33.33)29.6817
2010's3 (25.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.48 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (23.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (76.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
diacetyl
butane-2,3-dione : An alpha-diketone that is butane substituted by oxo groups at positions 2 and 3. It is a metabolite produced during the malolactic fermentation.		3.2710alpha-diketoneEscherichia coli metabolite;
Saccharomyces cerevisiae metabolite
gemfibrozil
[no description available]		1.9910aromatic etherantilipemic drug
ethylene oxide
Ethylene Oxide: A colorless and flammable gas at room temperature and pressure. Ethylene oxide is a bactericidal, fungicidal, and sporicidal disinfectant. It is effective against most micro-organisms, including viruses. It is used as a fumigant for foodstuffs and textiles and as an agent for the gaseous sterilization of heat-labile pharmaceutical and surgical materials. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p794). oxirane : A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom.		2.0510gas molecular entity;
oxacycle;
saturated organic heteromonocyclic parent		allergen;
mouse metabolite;
mutagen
malondialdehyde
Malondialdehyde: The dialdehyde of malonic acid.. malonaldehyde : A dialdehyde that is propane substituted by two oxo groups at the terminal carbon atoms respectively. A biomarker of oxidative damage to lipids caused by smoking, it exists in vivo mainly in the enol form.		2.0210dialdehydebiomarker
phenylglyoxal
[no description available]		3.2710phenylacetaldehydes
fructosamine
Fructosamine: An amino sugar formed when glucose non-enzymatically reacts with the N-terminal amino group of proteins. The fructose moiety is derived from glucose by the classical Amadori rearrangement.		2.0210
glutamic acid
Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM.. glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2.		3.2710glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical
chlorodiphenyl (54% chlorine)
Chlorodiphenyl (54% Chlorine): A mixture of polychlorinated biphenyls that induces hepatic microsomal UDP-glucuronyl transferase activity towards thyroxine.. Aroclor 1254 : A mixture of polychlorobiphenyls of unspecified composition, containing 54% chlorine (X = Cl or H).		3.2710
lovastatin
Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).		1.9910delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring)		anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug
salvin
salvin: a biocyclic diterpenoid; from sage and rosemary (Lamiaceae)		3.1310abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid		angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite
medica 16
MEDICA 16 : An alpha,omega-dicarboxylic acid that is hexadecanedioic acid carrying methyl groups at positions 3 and 14. It is a free fatty acid 1 (FFA1/GPR40) receptor agonist and an ATP citrate lyase inhibitor, and exhibits hypolipidemic and antidiabetogenic properties.		3.2710alpha,omega-dicarboxylic acidantilipemic drug;
EC 2.3.3.8 (ATP citrate synthase) inhibitor;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
G-protein-coupled receptor agonist;
hypoglycemic agent
hydroxycitric acid
hydroxycitric acid: RN given refers to cpd without isomeric designation; structure		2.0210carbonyl compound
clausenamide
clausenamide: Chinese drug isolated from leaves of Clausena lansium (Lour) Skeels; used in treatment of viral hepatitis; structure given in first source		2.0510
hydroxycitric acid
[no description available]		3.5420carbonyl compound
carnosol
carnosol: isolated from Lepechinia hastata		3.1310diterpenoid
lignans
Lignans: A class of dibenzylbutane derivatives which occurs in higher plants and in fluids (bile, serum, urine, etc.) in man and other animals. These compounds, which have a potential anti-cancer role, can be synthesized in vitro by human fecal flora. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed)		2.0510
acetyl coenzyme a
Acetyl Coenzyme A: Acetyl CoA participates in the biosynthesis of fatty acids and sterols, in the oxidation of fatty acids and in the metabolism of many amino acids. It also acts as a biological acetylating agent.		2.0210acyl-CoAacyl donor;
coenzyme;
effector;
fundamental metabolite
cucurbitacin b
[no description available]		3.2710cucurbitacin;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone
monorden
monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II		3.2710cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols		antifungal agent;
metabolite;
tyrosine kinase inhibitor
dalcetrapib
dalcetrapib: inhibits cholesteryl ester transfer protein (CETP)		3.1310anilide
sc 795
[no description available]		3.1310
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Exacerbation
[description not available]		02.9510
Atherogenesis
[description not available]		02.9510
Hyperlipemia
[description not available]		02.9510
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.9510
Atherosclerosis
A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA.		02.9510
Benign Neoplasms
[description not available]		03.6930
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.6930
Alexia
[description not available]		03.1710
Cancer of Pancreas
[description not available]		03.1740
Weight Reduction
[description not available]		02.2510
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		03.1740
Weight Loss
Decrease in existing BODY WEIGHT.		02.2510
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.2110
Autoimmune Diabetes
[description not available]		02.0210
Diabetes Mellitus, Adult-Onset
[description not available]		02.0210
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.0210
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.0210